Establishment of a humanized patient-derived xenograft mouse model of high-grade serous ovarian cancer for preclinical evaluation of combination immunotherapy - PubMed
5 hours ago
- #immunotherapy
- #ovarian cancer
- #mouse model
- Development of a humanized patient-derived xenograft mouse model for high-grade serous ovarian cancer (HGSOC).
- Model used to evaluate combination immunotherapy with durvalumab (anti-PD-L1) and oleclumab (anti-CD73).
- Treatment was well-tolerated but did not show significant antitumor response.
- Tumors exhibited an immune-excluded immunophenotype with no significant differences in disease burden or immune cell density.
- Positive correlation between tumor burden and intratumoral T-cell densities in the durvalumab-only group.
- Model reflects clinical immunotherapy resistance, providing a platform for studying tumor-immune interactions in HGSOC.